Gilead's oral α4β7 integrin inhibitor emvistegrast met the primary endpoint in Phase II SWIFT study for ulcerative colitis.
AbbVie (NYSE: ABBV) reported that its investigational dual-targeting combination ABBV-466 achieved primary endpoints in ...
Evaxion's personalized cancer vaccine EVX-01 kept all Phase II melanoma patients in response at three years, with no tumor ...
Nouscom closes oversubscribed EUR 120M Series D to advance NOUS-209 toward a Lynch syndrome registration trial. Learn what this means for patients.
FDA approves Ryzumvi label expansion for presbyopia, giving Viatris' phentolamine eye drop a second indication. Read the full details and clinical impact.
Microbiotica raised USD 48m in its Series C to advance MB310 into a Phase II ulcerative colitis study. Read the complete ...
Betta pan-RAS inhibitor BPI-572270 wins NMPA combination trial acceptance in China, plus Australian and US FDA trial ...
FDA grants orphan drug designation to GT801, an in vivo CAR-T for AIHA. Read how this Vivacta and Grit Bio therapy could ...
FDA unveils Rare Disease Framework Initiative to overhaul how rare-condition drugs are developed and reviewed. See how it ...
OrbiMed raises USD 3 billion across two private equity funds targeting life sciences and healthcare in the US, Europe, and ...
CHMP issues second negative opinion on narsoplimab (Yartemlea) for TA-TMA, leaving European patients without an approved ...
AMPfield's once-daily prifemilast beat apremilast on both co-primary endpoints in a Phase III psoriasis head-to-head trial.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results